No kidding! The RLFTF CEO got demoted from CEO to scientist. He screwed up the trial and has been replaced and is no longer in charge. So now the FDA is waiting for results from the professionally run trial by the NIH. Their drug has shown great efficacy after the new primary end points were adjusted, however the CEO made too many mistakes so the FDA has put their EUA on the back burner while they wait for NIH trial results.
I have owned and studied RVVTF. There is a very close comparison between the processes that RLFTF and RVVTF have been following. Different drugs, but very similar processes. IMO RVVTF won't see EUA approval until very late 2022 or early 2023 (assuming they meet their new primary end points). Clearly they failed to do so in the current trial (same thing happened to RLFTF).
Both RVVTF (as well as RLFTF) may prevail in the end, however the clock is ticking on the pandemic while other pharms have been getting FDA approvals. I've always felt that MF had placed his priorities on SHROOMS rather than Bucillamine, hence the slow start out of the gate once they got FDA approval to start Phase 3. That was the red flag for me and a big let down. Slow you blow, snooze you loose. Well, it's not too late, but he had better forgot about the shrooms and pull out all of the stops to push Bucillamine to the finish line!!
News 
Market Data 
Discover 
